TWI818954B - 三取代之苯并三唑衍生物的使用方法 - Google Patents

三取代之苯并三唑衍生物的使用方法 Download PDF

Info

Publication number: TWI818954B
Authority: TW; Taiwan
Prior art keywords: cancer; compound; cell lymphoma; leukemia; diffuse large
Prior art date: 2018-02-20

Application number

TW108105398A

Other languages

English (en)

Chinese (zh)

Other versions

TW201938543A (zh

Inventor

丹尼爾尤拉奈特

誠恩崔

Original Assignee

法商施維雅藥廠

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-02-20

Filing date

2019-02-19

Publication date

2023-10-21

2019-02-19 Application filed by 法商施維雅藥廠 filed Critical 法商施維雅藥廠

2019-10-01 Publication of TW201938543A publication Critical patent/TW201938543A/zh

2023-10-21 Application granted granted Critical

2023-10-21 Publication of TWI818954B publication Critical patent/TWI818954B/zh

Links

238000000034 method Methods 0.000 title abstract description 36
125000003354 benzotriazolyl group Chemical class N1N=NC2=C1C=CC=C2* 0.000 title abstract description 3
206010028980 Neoplasm Diseases 0.000 claims abstract description 64
201000011510 cancer Diseases 0.000 claims abstract description 52
150000003839 salts Chemical class 0.000 claims abstract description 24
208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 36
206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 36
150000001875 compounds Chemical class 0.000 claims description 31
208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 21
208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 21
238000011282 treatment Methods 0.000 claims description 17
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 15
229960000684 cytarabine Drugs 0.000 claims description 14
238000002512 chemotherapy Methods 0.000 claims description 10
206010033128 Ovarian cancer Diseases 0.000 claims description 8
206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
206010000871 Acute monocytic leukaemia Diseases 0.000 claims description 7
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 7
102100021631 B-cell lymphoma 6 protein Human genes 0.000 claims description 7
108091012583 BCL2 Proteins 0.000 claims description 7
101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 claims description 7
208000035489 Monocytic Acute Leukemia Diseases 0.000 claims description 7
201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 7
208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 6
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 5
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims description 5
208000036566 Erythroleukaemia Diseases 0.000 claims description 5
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 5
206010065857 Primary Effusion Lymphoma Diseases 0.000 claims description 5
208000021841 acute erythroid leukemia Diseases 0.000 claims description 5
201000009036 biliary tract cancer Diseases 0.000 claims description 5
208000020790 biliary tract neoplasm Diseases 0.000 claims description 5
201000006778 chronic monocytic leukemia Diseases 0.000 claims description 5
201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 5
201000007270 liver cancer Diseases 0.000 claims description 5
208000014018 liver neoplasm Diseases 0.000 claims description 5
208000025113 myeloid leukemia Diseases 0.000 claims description 5
230000004077 genetic alteration Effects 0.000 claims description 4
231100000118 genetic alteration Toxicity 0.000 claims description 4
208000011825 carcinoma of the ampulla of vater Diseases 0.000 claims description 3
201000009030 Carcinoma Diseases 0.000 claims description 2
239000003708 ampul Substances 0.000 claims 1
210000000514 hepatopancreas Anatomy 0.000 claims 1
229940125904 compound 1 Drugs 0.000 description 35
210000004027 cell Anatomy 0.000 description 27
235000002639 sodium chloride Nutrition 0.000 description 20
230000035945 sensitivity Effects 0.000 description 19
239000000203 mixture Substances 0.000 description 18
125000000217 alkyl group Chemical group 0.000 description 16
-1 c-MYC Proteins 0.000 description 16
230000012010 growth Effects 0.000 description 15
206010025323 Lymphomas Diseases 0.000 description 12
125000003118 aryl group Chemical group 0.000 description 12
239000004480 active ingredient Substances 0.000 description 10
229910052757 nitrogen Inorganic materials 0.000 description 10
239000000843 powder Substances 0.000 description 10
125000001072 heteroaryl group Chemical group 0.000 description 9
239000003981 vehicle Substances 0.000 description 9
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
150000003278 haem Chemical class 0.000 description 8
125000005842 heteroatom Chemical group 0.000 description 8
125000000623 heterocyclic group Chemical group 0.000 description 8
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 8
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 7
240000001717 Vaccinium macrocarpon Species 0.000 description 7
239000003814 drug Substances 0.000 description 7
230000009036 growth inhibition Effects 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
230000004614 tumor growth Effects 0.000 description 7
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 6
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 6
229910020008 S(O) Inorganic materials 0.000 description 6
238000003556 assay Methods 0.000 description 6
125000000753 cycloalkyl group Chemical group 0.000 description 6
229940079593 drug Drugs 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
235000012545 Vaccinium macrocarpon Nutrition 0.000 description 5
235000002118 Vaccinium oxycoccus Nutrition 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
235000004634 cranberry Nutrition 0.000 description 5
229910052736 halogen Inorganic materials 0.000 description 5
150000002367 halogens Chemical group 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
229910052739 hydrogen Inorganic materials 0.000 description 5
125000004433 nitrogen atom Chemical group N* 0.000 description 5
229910052760 oxygen Inorganic materials 0.000 description 5
125000001424 substituent group Chemical group 0.000 description 5
229910052717 sulfur Inorganic materials 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
238000011579 SCID mouse model Methods 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
125000002619 bicyclic group Chemical group 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
125000000592 heterocycloalkyl group Chemical group 0.000 description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
208000032839 leukemia Diseases 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
125000002950 monocyclic group Chemical group 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
239000001993 wax Substances 0.000 description 4
208000003950 B-cell lymphoma Diseases 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
125000000732 arylene group Chemical group 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000007884 disintegrant Substances 0.000 description 3
239000000975 dye Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000003394 haemopoietic effect Effects 0.000 description 3
201000005787 hematologic cancer Diseases 0.000 description 3
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000010410 layer Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
229960004618 prednisone Drugs 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
PAPNRQCYSFBWDI-UHFFFAOYSA-N 2,5-Dimethyl-1H-pyrrole Chemical compound CC1=CC=C(C)N1 PAPNRQCYSFBWDI-UHFFFAOYSA-N 0.000 description 2
XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 2
NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
206010063045 Effusion Diseases 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
102000043276 Oncogene Human genes 0.000 description 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
102000047164 SAM Domain and HD Domain-Containing Protein 1 Human genes 0.000 description 2
108700019718 SAM Domain and HD Domain-Containing Protein 1 Proteins 0.000 description 2
101150114242 SAMHD1 gene Proteins 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
238000011226 adjuvant chemotherapy Methods 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000008272 agar Substances 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
238000013459 approach Methods 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
239000000440 bentonite Substances 0.000 description 2
229910000278 bentonite Inorganic materials 0.000 description 2
235000012216 bentonite Nutrition 0.000 description 2
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
239000004305 biphenyl Substances 0.000 description 2
235000010290 biphenyl Nutrition 0.000 description 2
210000003969 blast cell Anatomy 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
235000021019 cranberries Nutrition 0.000 description 2
229960004397 cyclophosphamide Drugs 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000011049 filling Methods 0.000 description 2
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
239000000463 material Substances 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
125000004430 oxygen atom Chemical group O* 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
238000010837 poor prognosis Methods 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
230000008707 rearrangement Effects 0.000 description 2
229960004641 rituximab Drugs 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000011255 standard chemotherapy Methods 0.000 description 2
238000011272 standard treatment Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000011593 sulfur Chemical group 0.000 description 2
239000000725 suspension Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
229940045145 uridine Drugs 0.000 description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
229960004528 vincristine Drugs 0.000 description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical compound CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 description 1
MWZDIEIXRBWPLG-UHFFFAOYSA-N 1-methyl-1,2,4-triazole Chemical compound CN1C=NC=N1 MWZDIEIXRBWPLG-UHFFFAOYSA-N 0.000 description 1
MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
FGYADSCZTQOAFK-UHFFFAOYSA-N 1-methylbenzimidazole Chemical compound C1=CC=C2N(C)C=NC2=C1 FGYADSCZTQOAFK-UHFFFAOYSA-N 0.000 description 1
OMAFFHIGWTVZOH-UHFFFAOYSA-N 1-methyltetrazole Chemical compound CN1C=NN=N1 OMAFFHIGWTVZOH-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
206010004593 Bile duct cancer Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
208000018240 Bone Marrow Failure disease Diseases 0.000 description 1
206010065553 Bone marrow failure Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
125000005915 C6-C14 aryl group Chemical group 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 description 1
102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010066476 Haematological malignancy Diseases 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920000715 Mucilage Polymers 0.000 description 1
UQFQONCQIQEYPJ-UHFFFAOYSA-N N-methylpyrazole Chemical compound CN1C=CC=N1 UQFQONCQIQEYPJ-UHFFFAOYSA-N 0.000 description 1
RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001494479 Pecora Species 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
241000282887 Suidae Species 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010066901 Treatment failure Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
210000004141 ampulla of vater Anatomy 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000008122 artificial sweetener Substances 0.000 description 1
235000021311 artificial sweeteners Nutrition 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
229960002756 azacitidine Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000002902 bimodal effect Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
238000012054 celltiter-glo Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000009104 chemotherapy regimen Methods 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
229960002436 cladribine Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
238000009096 combination chemotherapy Methods 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
229940059359 dacogen Drugs 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
229940026692 decadron Drugs 0.000 description 1
229960003603 decitabine Drugs 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000021185 dessert Nutrition 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
235000019797 dipotassium phosphate Nutrition 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000009093 first-line therapy Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000005454 flavour additive Substances 0.000 description 1
229960000390 fludarabine Drugs 0.000 description 1
229960005304 fludarabine phosphate Drugs 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
238000000227 grinding Methods 0.000 description 1
125000004438 haloalkoxy group Chemical group 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
125000004446 heteroarylalkyl group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
208000021173 high grade B-cell lymphoma Diseases 0.000 description 1
229940096120 hydrea Drugs 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
229960001330 hydroxycarbamide Drugs 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000001525 mentha piperita l. herb oil Substances 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229920003052 natural elastomer Polymers 0.000 description 1
229920001194 natural rubber Polymers 0.000 description 1
235000021096 natural sweeteners Nutrition 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000002547 new drug Substances 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000011236 particulate material Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
235000019477 peppermint oil Nutrition 0.000 description 1
210000003516 pericardium Anatomy 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
210000004224 pleura Anatomy 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000004302 potassium sorbate Substances 0.000 description 1
235000010241 potassium sorbate Nutrition 0.000 description 1
229940069338 potassium sorbate Drugs 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229950008679 protamine sulfate Drugs 0.000 description 1
239000011241 protective layer Substances 0.000 description 1
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000008261 resistance mechanism Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
238000011268 retreatment Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
239000012748 slip agent Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
SRWFBFUYENBCGF-UHFFFAOYSA-M sodium;chloride;hydrochloride Chemical compound [Na+].Cl.[Cl-] SRWFBFUYENBCGF-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000011301 standard therapy Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229920003051 synthetic elastomer Polymers 0.000 description 1
239000005061 synthetic rubber Substances 0.000 description 1
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
125000000101 thioether group Chemical group 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
229940065658 vidaza Drugs 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1
229930195724 β-lactose Natural products 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TW108105398A 2018-02-20 2019-02-19 三取代之苯并三唑衍生物的使用方法 TWI818954B (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
??PCT/US18/18679		2018-02-20
WOPCT/US18/18679		2018-02-20
US2018018679		2018-02-20

Publications (2)

Publication Number	Publication Date
TW201938543A TW201938543A (zh)	2019-10-01
TWI818954B true TWI818954B (zh)	2023-10-21

Family

ID=61692059

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW108105398A TWI818954B (zh)	2018-02-20	2019-02-19	三取代之苯并三唑衍生物的使用方法

Country Status (13)

Country	Link
US (2)	US11717512B2 (fr)
EP (1)	EP3755324B1 (fr)
JP (2)	JP7434185B2 (fr)
KR (1)	KR102861339B1 (fr)
CN (1)	CN111757731B (fr)
AU (1)	AU2019223906B2 (fr)
BR (1)	BR112020016929A8 (fr)
CA (1)	CA3091792A1 (fr)
ES (1)	ES3038736T3 (fr)
MA (1)	MA51897A (fr)
MX (1)	MX2020008678A (fr)
TW (1)	TWI818954B (fr)
WO (1)	WO2019164794A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MA48459B1 (fr)	2017-04-24	2021-09-30	Aurigene Discovery Tech Ltd	Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase
US20180369206A1 (en)	2017-04-24	2018-12-27	Aurigene Discovery Technologies Limited	Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
MX2020008678A (es)	2018-02-20	2020-09-25	Servier Lab	Metodos de uso para derivados de benzotriazol trisustituidos.
JP2022515239A (ja) *	2018-12-21	2022-02-17	レラボラトワールセルヴィエソシエテ・パール・アクシオンス・サンプリフィエ	有機化合物の結晶および塩形態およびその医薬組成物
CN111662872A (zh) *	2020-05-06	2020-09-15	西南医科大学附属医院	一种急性t淋巴细胞白血病阿糖胞苷耐药细胞株构建方法
WO2021262874A1 (fr)	2020-06-24	2021-12-30	Servier Pharmaceuticals , Llc	Utilisation d'un composé inhibiteur de dhodh en polythérapie anticancéreuse
JP2023533489A (ja)	2020-06-24	2023-08-03	レラボラトワールセルビエ	癌併用療法におけるｄｈｏｄｈ阻害剤化合物の利用
CN116847874A (zh) *	2020-08-27	2023-10-03	瑟维尔实验室	Dhodh抑制剂化合物在组合癌症疗法中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI372758B (en) *	2004-09-22	2012-09-21	Janssen Pharmaceutica Nv	Inhibitors of the interaction between mdm2 and p53
WO2014128669A2 (fr) *	2013-02-25	2014-08-28	Aurigene Discovery Technologies Limited	Dérivés de benzotriazole trisubstitués à titre d'inhibiteurs de dihydroorotate oxygénase
TW201902880A (zh) *	2017-04-24	2019-01-16	印度商阿瑞吉探索科技股份有限公司	使用三取代苯并三唑衍生物作為二氫乳清酸氧合酶抑制劑之方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI974171A7 (fi)	1995-05-10	1997-11-07	Pfizer	Metotreksaatin ja tenidapin yhdistelmä nivelreuman hoitoon
US6841561B1 (en)	1999-10-01	2005-01-11	Institute Of Molecular And Cell Biology	Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
JP2003510352A (ja)	1999-10-01	2003-03-18	インスティチュートオブモレキュラーアンドセルバイオロジー	ウイルス媒介性疾病の治療用化合物
WO2003006424A1 (fr)	2001-07-10	2003-01-23	4Sc Ag	Nouveaux composes utilises comme agents anti-inflammatoires, immunomodulateurs et anti-proliferatoires
MX2007002208A (es)	2004-08-25	2007-05-08	Targegen Inc	Compuestos hetrociclicos y metodos de uso.
JP2007015952A (ja)	2005-07-06	2007-01-25	Shionogi & Co Ltd	ナフタレン誘導体
DE102005049953A1 (de)	2005-10-19	2007-04-26	Sanofi-Aventis Deutschland Gmbh	Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen
KR101177729B1 (ko)	2006-09-08	2012-09-07	에프. 호프만-라 로슈 아게	벤조트리아졸 키나아제 조절제
EP2387568A1 (fr)	2009-01-19	2011-11-23	NeuroSearch A/S	Nouveaux dérivés de benzotriazole utiles pour le traitement de troubles du snc
EP2230232A1 (fr)	2009-03-13	2010-09-22	Almirall, S.A.	Sels adjuvants de trométhamine dotés de dérivés d'acide azabiphénylaminobenzoïque en tant qu'inhibiteurs de la DHOD
EP2228367A1 (fr)	2009-03-13	2010-09-15	Almirall, S.A.	Sels adjuvants d'amines contenant des groupes hydroxyle et/ou carbonyle avec des dérivés d'acides aminonicotiques en tant qu'inhibiteurs de la DHODH
US9316632B2 (en)	2009-03-17	2016-04-19	Marshall University Research Corporation	Methods of screening chemotherapeutic agents and treating cancer
NZ595819A (en)	2009-04-02	2013-02-22	Merck Serono Sa	DIHYDROOROTATE DEHYDROGENASE INHIBITORS; benzimidazole-4-carboxylic acid
EP2509600B1 (fr)	2009-12-09	2017-08-02	Agios Pharmaceuticals, Inc.	Composés thérapeutiquement actifs destinés au traitement d'un cancer caractérisé par une mutation idh
WO2011143160A2 (fr)	2010-05-10	2011-11-17	The Johns Hopkins University	Inhibiteur métabolique contre des tumeurs ayant une mutation de l'idh
US9012464B2 (en)	2010-11-25	2015-04-21	Ratiopharm Gmbh	Salts and polymorphic forms of Afatinib
WO2013049112A1 (fr)	2011-09-27	2013-04-04	Emory University	Détection de biomarqueurs à l'aide de résonance magnétique
CN103965133B (zh)	2013-01-31	2018-11-30	华东理工大学	一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
US9603927B2 (en)	2014-02-28	2017-03-28	Janssen Biotech, Inc.	Combination therapies with anti-CD38 antibodies
ES2960598T3 (es)	2014-05-08	2024-03-05	Kiora Pharmaceuticals Gmbh	Compuestos para el tratamiento de enfermedades y trastornos oftálmicos
CA2996632C (fr)	2015-09-01	2023-10-17	Bayer Pharma Aktiengesellschaft	Composes et methodes utiles pour le traitement ou la prevention de cancers hematologiques
KR20180102105A (ko)	2015-12-30	2018-09-14	아지오스 파마슈티컬스 아이엔씨.	돌연변이체 이소시트레이트 데히드로게나제를 포함하고 있는 종양의 치료
JOP20190094A1 (ar)	2016-10-27	2019-04-25	Broad Inst Inc	مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
WO2018136009A1 (fr)	2017-01-20	2018-07-26	Aslan Pharmaceuticals Pte Ltd	Polythérapie
US11311548B2 (en)	2017-03-02	2022-04-26	Aslan Pharmaceuticals Pte. Ltd.	Cancer therapy
US20180369206A1 (en)	2017-04-24	2018-12-27	Aurigene Discovery Technologies Limited	Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
WO2019012030A1 (fr)	2017-07-13	2019-01-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Inhibiteur de dhodh et inhibiteur de chk1 pour le traitement du cancer
MX2020008678A (es) *	2018-02-20	2020-09-25	Servier Lab	Metodos de uso para derivados de benzotriazol trisustituidos.
EP3858361B1 (fr)	2018-09-28	2025-10-08	FUJIFILM Corporation	Agent antitumoral contenant de la cytarabine, activateur d'effet antitumoral utilisé en combinaison avec la cytarabine, kit antitumoral, et agent antitumoral utilisé en combinaison avec le cytarabine
WO2020109625A1 (fr)	2018-11-30	2020-06-04	Fondazione Centro San Raffaele	Traitement combiné du lymphome primaire du système nerveux central
JP2022515239A (ja)	2018-12-21	2022-02-17	レラボラトワールセルヴィエソシエテ・パール・アクシオンス・サンプリフィエ	有機化合物の結晶および塩形態およびその医薬組成物
US12582667B2 (en)	2019-09-27	2026-03-24	The Rockefeller University	Compositions and methods to treat metastatic gastrointestinal cancer
JP2023533489A (ja)	2020-06-24	2023-08-03	レラボラトワールセルビエ	癌併用療法におけるｄｈｏｄｈ阻害剤化合物の利用
WO2021262874A1 (fr)	2020-06-24	2021-12-30	Servier Pharmaceuticals , Llc	Utilisation d'un composé inhibiteur de dhodh en polythérapie anticancéreuse
CN116847874A (zh)	2020-08-27	2023-10-03	瑟维尔实验室	Dhodh抑制剂化合物在组合癌症疗法中的用途

2019
- 2019-02-19 MX MX2020008678A patent/MX2020008678A/es unknown
- 2019-02-19 WO PCT/US2019/018472 patent/WO2019164794A1/fr not_active Ceased
- 2019-02-19 EP EP19707683.9A patent/EP3755324B1/fr active Active
- 2019-02-19 US US16/971,199 patent/US11717512B2/en active Active
- 2019-02-19 JP JP2020566525A patent/JP7434185B2/ja active Active
- 2019-02-19 BR BR112020016929A patent/BR112020016929A8/pt unknown
- 2019-02-19 MA MA051897A patent/MA51897A/fr unknown
- 2019-02-19 CA CA3091792A patent/CA3091792A1/fr active Pending
- 2019-02-19 TW TW108105398A patent/TWI818954B/zh active
- 2019-02-19 KR KR1020207024137A patent/KR102861339B1/ko active Active
- 2019-02-19 ES ES19707683T patent/ES3038736T3/es active Active
- 2019-02-19 CN CN201980014469.1A patent/CN111757731B/zh active Active
- 2019-02-19 AU AU2019223906A patent/AU2019223906B2/en active Active
2023
- 2023-05-29 JP JP2023087801A patent/JP2023109974A/ja active Pending
- 2023-06-09 US US18/207,887 patent/US12290508B2/en active Active

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI372758B (en) *	2004-09-22	2012-09-21	Janssen Pharmaceutica Nv	Inhibitors of the interaction between mdm2 and p53
WO2014128669A2 (fr) *	2013-02-25	2014-08-28	Aurigene Discovery Technologies Limited	Dérivés de benzotriazole trisubstitués à titre d'inhibiteurs de dihydroorotate oxygénase
TW201902880A (zh) *	2017-04-24	2019-01-16	印度商阿瑞吉探索科技股份有限公司	使用三取代苯并三唑衍生物作為二氫乳清酸氧合酶抑制劑之方法

Also Published As

Publication number	Publication date
EP3755324C0 (fr)	2025-07-30
MA51897A (fr)	2020-12-30
AU2019223906A1 (en)	2020-09-10
EP3755324B1 (fr)	2025-07-30
MX2020008678A (es)	2020-09-25
US12290508B2 (en)	2025-05-06
CN111757731A (zh)	2020-10-09
JP2021514395A (ja)	2021-06-10
BR112020016929A2 (pt)	2020-12-15
CA3091792A1 (fr)	2019-08-29
KR102861339B1 (ko)	2025-09-19
JP2023109974A (ja)	2023-08-08
TW201938543A (zh)	2019-10-01
ES3038736T3 (en)	2025-10-14
AU2019223906B2 (en)	2024-11-21
JP7434185B2 (ja)	2024-02-20
EP3755324A1 (fr)	2020-12-30
WO2019164794A1 (fr)	2019-08-29
KR20200123137A (ko)	2020-10-28
BR112020016929A8 (pt)	2022-06-28
US20210113531A1 (en)	2021-04-22
US11717512B2 (en)	2023-08-08
US20240148697A1 (en)	2024-05-09
CN111757731B (zh)	2024-06-25

Publication	Publication Date	Title
TWI818954B (zh)	2023-10-21	三取代之苯并三唑衍生物的使用方法
US20210100805A1 (en)	2021-04-08	Combination therapy for treating malignancies
MD3362066T2 (ro)	2022-08-31	Terapie combinată pentru tratamentul tumorilor maligne
TW201306842A (zh)	2013-02-16	使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
US20130101680A1 (en)	2013-04-25	Radiotherapy enhancer
KR102687556B1 (ko)	2024-07-22	종양 전이를 억제하는 방법
HK40043674A (en)	2021-09-17	Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
HK40043674B (en)	2025-09-26	Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
CN105251023A (zh)	2016-01-20	AXL/c-Met抑制剂在制备逆转肾癌舒尼替尼耐药的药物中的应用
CN115120732B (zh)	2025-05-30	一种喹唑啉化合物的药物组合物及其制备方法
HK40121691A (zh)	2025-09-19	治疗cdk4/6抑制剂耐药性癌症的方法
CN121059588A (zh)	2025-12-05	一种抗肿瘤药物及其应用
CN101155782A (zh)	2008-04-02	以吡啶衍生物为有效成分的放射线治疗增强剂
JP2019182764A (ja)	2019-10-24	慢性脂肪性疾患の予防および治療用医薬
HK1118807A1 (en)	2009-02-20	Potentiator for radiation therapy comprising pyridine derivative as active ingredient
HK1118807B (en)	2011-09-16	Potentiator for radiation therapy comprising pyridine derivative as active ingredient
BR122024020713A2 (pt)	2024-11-12	Uso de composto em terapia de combinação para tratamento de doenças malignas
BR122024000250B1 (pt)	2025-01-28	Uso de um inibidor de desidrogenase isocitrato1 (IDH1) mutante e um agente desmetilante